Indrajit Sinha, PhD, MBA

Dr. Indrajit Sinha brings over 30 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, Intellectual Property,  technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer-reviewed journals. Through his passion for utilizing underappreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property linked business opportunities since 2000. 

In 2001, Dr. Sinha founded Medhospital Inc. Medhospital’s vision was to simplify the complex language and terminologies of healthcare and biomedicine to empower families in understanding and managing their health needs better. In 2011, he founded Biomedcore Inc. where he developed and patented a unique protocol that effectively enables accelerated individualized prediction of cancer progression and response to treatment. This technology has been granted a patent in multiple jurisdictions and is being validated for clinical utility. Through a partnership with Suntrition Inc., a Natural Health Product manufacturing company, he evolved it into a unique health solutions company, Acenzia Inc. Acenzia built a certified facility that seamlessly coordinated diagnostics and manufacturing services to the health and dietary supplement industry under one roof. Acenzia was sold to Novo Integrated Sciences Inc. in 2021. 

Dr. Sinha has been actively involved in technology start-ups and investment communities for more than ten years. He has advised and evaluated  companies through Ontario Centers of Innovations (OCI) and has successfully raised fundings from OCI, the Natural Sciences and Engineering Research Council of Canada (NSERC), MITACS (empowers Canadian innovation through effective partnerships), Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA), FedDev Ontario, and the National Research Council of Canada (NRC). Given the nature of projects he is involved in, Dr. Sinha also helps companies file for Scientific Research and Experimental Development (SR&ED) tax incentives in Canada. 

Honours and Awards

  • 2016: Phil Marder Award, GLIIFCA Scientific meeting, Michigan, USA 
  • 2013-2016: Technology Innovation Feasibility Project (TIFP), National Research Council of Canada, IRAP
  • 2013: Research Tools and Instruments (RTI), Natural Sciences and Engineering Research Council of Canada, 2012-2013: Technical Problem Solving (TPS), Ontario Centres of Excellence (OCE) 
  • 2012-2013: Applied Research and Commercialization (ARC), FedDev Ontario 
  • 2012-2013: VentureStart, FedDev Ontario 
  • 2011: Odette Project for Technology, Innovation and Commercialization (OPTIC), Ontario Ministry of Economic Development and Trade, The Windsor Essex Economic Development Corporation and the Odette School of Business. 
  • 2000-2001: Research Fellowship, Department of Science and Technology, New Delhi, India. 
  • 1996-2000: Research Fellowship, University Grants Commission, New Delhi, India. 
  • 1995-1996: Research Fellowship, Ministry of Environment and Forests, New Delhi, India. 
  • 1993-1995: Student Scholarship, Department of Biotechnology, New Delhi, India.

Education
  1. 2021-2023
    Executive MBA from the University of Cumbria, UK
  2. 2008-2010
    Post-doctoral, Wayne State University and Karmanos Cancer Institute in Detroit Michigan, USA
  3. 2001-2007
    Post-doctoral, National University of Singapore and the Agency for Science, Technology and Research (A*STAR), Singapore
  4. 1995-2000
    PhD in Microbiology, Delhi University, India
  5. 1995-2000
    MSc in Biotechnology, MS University of Baroda, India

Publications

Patents 
  • Sinha, I.(2012). Accelerated prediction of cancer progression and response to treatment. (CA2893549, WO2014083555A1, US20150315546A1, EP2925890A4, JP2016501021A, CN105121657A.) Awarded in Singapore, Japan, USA, rest under office action. 

Peer Reviewed Research Papers
  • Crozier, M., Tubman, J., Fifield, B-A., Ferraiuolo, R-M., Ritchie, J., Zuccato, K., Mailloux, E., Sinha, I., Hamm, C., Porter, L. (2022). Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells. PLoS ONE 17(9): e0274675.
  • Wright III,R.E., Shahin,L., Gogineni,V., Hussain, Z., Naeem, A., Sadasivan, S., Sinha, I., Neely, M., Michellhaugh, S.K., Mittal, S., Joshee, N. and Parajuli, P. (2021). Scutellaria Extract Inhibits Proliferation and Migration of Brain- Metastatic Lung Cancer Cells via Regulation of Multiple Signaling Pathways J. Medicin. Activ. Plant. 10:32-41.  
  • He Q., Au, B., Kulkarni, M., Shen, Y., Lim, K.J., Maimati, J., Wong, C.K., Luijten, M.N.H., Chong, H.C., Lim, E.H., Rancati, G., Sinha, I., Fu, Z., Wang, X., Connolly, J.E., Crasta, K. (2018). Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects. Oncogenesis. 7: 62. 
  • Jakhar, R., Luijten, M.N.H., Wong, A.X.F., Cheng, B., Neo, S.P., Au, B., Kulkarni, M.D., Lim, K.J., Maimaiti, J., Chong, H.C., Lim, E.H., Tan, T.B.K., Ong, K.W., Sim, Y., Wong, J.S.L., Khoo, J.B.K., Ho, J.T.S., Guo, K., Chua, B.T., Sinha, I., Wang, X., Connolly, J.E., Gunaratne, J. And Crasta, K.C. (2018). Autophagy governs protumorigenic effects of mitotic slippage-induced senescence. Mol. Cancer Res. 16:1625-1640. 
  • Ferraiuolo, R-M., Tubman, J., Sinha, I., Hamm, C. and Porter, L. (2017). The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting Tamoxifen resistance. Oncotarget 8: 23337-23352. 
  • Tan, D.S.W., Haaland, B., Gan, J.M., Tham, S.C., Sinha, I., Tan, E.H., Lim, K.H., Takano, A., Krisna, S.S., Myint Thu, M.M., Liew, H.P., Ullrich, A., Lim, W.T. and Chua, B.T. (2014). Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. Mol. Cancer. 13: 13. 
  • Venuprasad, K., Ahmed, N., Zeng, M., Polin, L. Sinha, I., Rathinam, C., Flavell, R. and Massoumi, R. (2013). The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. J. Immunol. 190: 170.10. 
  • Ahmed, N., Zeng, M., Sinha, I., Polin, L., Wei W-Z., Rathinam, C., Flavell, R., Massoumi, R. & Venuprasad, K. (2011) The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 2: 1176-1183. 
  • Zhang, T., Nirantar, S., Lim, H.H., Sinha, I. & Surana, U. (2009) DNA damage checkpoint maintains Cdh1 in an active state to inhibit anaphase progression. Dev. Cell 17: 541-551. 
  • Sinha, I., Wang, Y.M., Philp, R., Li, C.R., Yap, W.H. & Wang, Y. (2007) Cyclin-dependent kinases control septin phosphorylation in Candida albicans hyphal development. Dev. Cell 13: 421-432. 
  • Sinha, I. & Dick, T. (2004) Role of malonyl coenzyme A: Acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG. J. Antimicrob. Chemother. 53: 1072-1075. 
  • Sinha, I., Boon, C. & Dick, T. (2003) Apparent growth phase-dependent phosphorylation of malonyl coenzyme A: Acyl carrier protein transacylase (MCAT), a major fatty acid synthase II component in Mycobacterium bovis BCG. FEMS Microbiol. Lett. 227: 141-147. 
  • Virdi, J.S., Sinha, I., Rajendran P. & Singh I. (2001) Arsenite-induced multiple antibiotic resistance phenotypes in environmental isolates of Yersinia enterocolitica. Curr. Microbiol. 43: 144-146. 
  • Sinha, I. & Virdi, J. S. (2000) Differentiation of non-pathogenic (biotype 1A) Yersinia enterocolitica from pathogenic bioserotypes by sodium acetate utilization. J. Med. Microbiol. 49: 674-676. 
  • Bansal, N., Sinha, I. & Virdi, J.S. (2000) Virulence plasmid (pYV)-associated susceptibility of Yersinia enterocolitica to chlorine and heavy metals. J. Appl.Microbiol. 89: 663-667. 
  • Bansal, N., Sinha, I. & Virdi, J.S. (2000) Arsenic and cadmium resistance in environmental isolates of Yersinia enterocolitica and Yersinia intermedia. Can. J. Microbiol. 46: 481-484.  
  • Sinha, I. & Virdi, J.S. (2000) In vitro antibiotic susceptibilities of Yersinia enterocolitica and Yersinia intermedia isolated from sewage effluents. Curr. Sci. 79: 90-92. 
  • Sinha, I. & Virdi, J.S. (2000) Isolation of Yersinia enterocolitica and Yersinia intermedia from wastewaters and their biochemical and serological characteristics. Curr. Sci. 2000, 79: 510-513. 

Book Chapter
  • Virdi, J.S., Sachdeva, S., Bhagat, N., Singh, I., Sinha, I., Sharma, S., Mallik, S., Mittal, S. (2005). Serological and molecular diversity of Yersinia enterocolitica isolated from India. In: Molecular diversity. Current perspectives and potential applications (Edited by T. Satyanarayana and B.N. Johri). Published by IK International Pvt. Ltd., New Delhi. pp. 1037-1052. 

White Paper
  • Li, F., Maimaiti, J., McConnell, C., Tubman, J., Porter, L., Sinha, I. and Lim K.J. (2018). Design and development of an antioxidant formulation with measurable effects against oxidative stress, infection induced inflammation, and vascular development during tumour induced angiogenesis. 

Conference Presentations
  • Sinha, I. (2017). A Rapid, In Vivo Zebrafish Model to Elucidate the Micrometastatic Potential of Human Lung Cancer Cells. Oral presentation at CYTO 2017 Scientific meeting, Boston, USA, Jun 10-15. 
  • Sinha, I. (2016). A Rapid, In Vivo Zebrafish Model to Elucidate the Micrometastatic Potential of Human Lung Cancer Cells. Oral presentation at GLIIFCA Scientific meeting, Michigan, USA.  
  • Tubman, J., Sinha, I. and Porter, LA. (2014). A role of Spy1 in breast cancer metastasis. Poster presentation at Cold Spring Harbour Mechanisms and Models of Cancer, Cold Spring Harbour, NY, Aug 29. 
  • Benchaala, I., Sinha, I., Hali, M., Gerard, H., Bharatwaj, B, Hudson., A., Rocha, S. and Whittum-Hudson, J. (2011). Reduction in Chlamydia trachomatis-associated murine reactive arthritis by novel peptide vaccine candidates. Oral presentation at ACR/ARHP Scientific meeting 11, Chicago, USA, Nov 5-9. 
  • Whittum-Hudson, J., Hali, M., Sinha, I., Bharatwaj, B., Oszust, C., Hudson, A. and da Rocha, S. (2011). Novel Mimotope Peptides as anti-chlamydial vaccine candidates. Poster presentation at 15th International Congress of Mucosal Immunology, Paris, France, July 5-9. 
  • Peng, D.J., Sinha, I., Zeng, M., Subramaniam, M., Spelsberg, T.C. and Venuprasad, K. (2010). Non-canonical K-27 linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. Poster presentation at 39th Autumn Immunology Conference, Chicago, IL, USA, Nov. 19-22. 
  • Bonneau, P., Macpharlin, C., Hali, M., Benchaala, I., Sinha, I., Kannan, R., Mishra, M. and Whittum-Hudson, J. (2010). Characterizing Therapeutic Effects of Antibiotic-loaded Nanodevices in Chlamydial Infections. Medical student summer research symposium, Chemical Engineering & Materials Science, College of Engineering, Wayne State University, Detroit, USA. 
  • Mishra, M.K., Kotta, K., Benchaala, I., Wykes, S.M., Hali, M., Sinha, I., Whittum-Hudson, J. and Kannan, R.M. (2009) Development of Folate-PAMAM and Azithromycin-PAMAM Nanodevices for Biodistribution, Imaging, Cellular Uptake, and Targeted Delivery to Chlamydial Infections. Poster presentation at AIChE Annual Meeting, Nashville, TN, USA, Nov. 8-13. 
  • Benchaala, I., Sinha, I., Wykes, S.M., Hali, M., Mishra, M., Kotta, K., Kannan, R.M., Whittum-Hudson, J.A. (2009) Targeted delivery of Nanoparticles to Chlamydia trachomatis–infected tissues in murine reactive arthritis. Oral presentation at ACR/ARHP Scientific meeting 09, Philadelphia, Pennsylvania, USA, Oct 17-21. 
  • Mishra, M.K., Kotta, K., Benchaala, I., Wykes, S., Hali, M., Sinha, I., Whittum-Hudson, J. and Kannan, R.M. (2009) Development of PAMAM-dendrimer based nanodevices for targeted delivery to Chlamydia trachomatis infection. Poster presentation at Nanoscience: Challenges for the Future: 237th ACS National Meeting & Exposition, Salt Lake City, UT, Mar. 22-26. 
  • Sinha, I., Oszust, C., Sekhon, K., Wu, L. Hali, M., da Rocha, S., Hudson, A., Whittum-Hudson, J. (2009) Test of novel peptides as anti-chlamydial vaccine candidates. Oral presentation at CBRS 2009: 4th Biennial Meeting of the Chlamydia Basic Research Society, Little Rock, Arkansas, USA, Mar. 20-23. 
  • Whittum-Hudson, J., Benchaala, I., Wykes, S., Hali, M., Sinha, I., Mishra, M., Kotta, K., Kannan, R.M. (2009) Development of PAMAM-dendrimer based nanodevices for targeted delivery to Chlamydia trachomatis infection. Poster presentation at CBRS 2009: 4th Biennial Meeting of the Chlamydia Basic Research Society, Little Rock, Arkansas, USA, Mar. 20-23. 
  • Sekhon, K., Wykes, S., Sovinski, A., Toti, U., Hali, M., Sinha, I., Gérard, H., Hudson, A., Panyam, J., Whittum-Hudson, J. (2009)  Use of nanotechnology to target acutely and persistently Chlamydia-infected cells for therapy and imaging in vitro and in vivo. Poster presented at CBRS 2009: 4th Biennial Meeting of the Chlamydia Basic Research Society, Little Rock, Arkansas, USA, Mar. 20-23. 
  • Sinha, I., Wang, Y.M., Philp, R., Li, C.R., Yap, W.H. and Wang, Y. (2008) Septin phosphorylation in Candida albicans during hyphal development. ASM Conferences: 9th Candida and Candidiasis, Jersey City, NJ, USA, Mar. 24-28. 
  • Sinha, I. and Dick, T. (2004) Role of malonyl coenzyme A: Acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG.  Oral presentation at NITD Inaugural Symposium on Dengue Fever and Tuberculosis, Singapore, Jul. 5-6. 
  • Sinha, I., Boon, C. and Dick, T. (2003) Growth phase-dependent Proteome phosphorylation in Mycobacterium bovis BCG. Poster presentation at the 103rd ASM conference, Washington DC, USA, May. 2003. 
  • Sinha, I., Boon, C. and Dick, T. (2003) Growth phase-dependent Proteome phosphorylation in Mycobacterium bovis BCG. Oral presentation at NITD Inaugural Symposium on Dengue Fever and Tuberculosis, Singapore, Jan. 22-23.  
  • Sinha, I., Boon C., and Dick, T. (2002) Growth phase-independent proteome phosphorylation in Mycobacterium bovis BCG. Oral presentation at the Second International Conference on Structural Biology and Functional Genomics, Singapore, Dec. 2-4. 
  • Sinha, I. and Virdi, J. S. (2000) Environmental Yersinia enterocolitica biotype 1A produce water-soluble siderophore(s) but lack yersiniophore. Oral presentation at 40th Annual Conference of AMI at Bhubaneswar, India. Jan. 22-24.  
Search